Hématologie Myélodysplasie QPL-MDS Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS) Saint-Cloud SANDRA MALAK
Appareil Digestif IMMUNO-BIL (D48-1 PRODIGE 57) Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study Saint-Cloud
Hématologie Lymphome non Hodgkinien BLOCAGE 01 Phase III Trial Evaluating Maintenance Treatment Versus Observation in Elderly Patients Suffering From Primary Central Nervous System Lymphoma in Complete Remission After High Dose Methotrexate Based Chemotherapy in First Line Saint-Cloud CAROLE SOUSSAIN
Hématologie Lymphome non Hodgkinien GATA A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas Saint-Cloud CAROLE SOUSSAIN
Appareil Digestif APACaP Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer Saint-Cloud
Recherches "plusieurs pathologies" DERMACLIC (IC 2019-12) Study on skin toxicities induced by cancer treatments Paris
Sein métastatique RH+ DOLAF An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib Saint-Cloud
Recherches "plusieurs pathologies" MCLA-128-CL01 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion Saint-Cloud
VADS NIVOPOST-OP / GORTEC 2018-01 A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP) Paris, Saint-Cloud CHRISTOPHE LE TOURNEAU, LAURENCE BOZEC
VADS TG4050.02 A randomized phase I trial in patients with newly-diagnosed, locoregionally advanced, HPV-negative, squamous cell carcinoma of the head and neck (SCCHN);evaluating a mutanome-directed immunotherapy;initiated at completion of primary treatment or at time of recurrence Paris CHRISTOPHE LE TOURNEAU